Maria Thacker Goethe on Biotech Growth, Clinical Trials & US Competitiveness

Georgia's life sciences industry is growing fast. Biotech manufacturing, clinical trials, workforce development, and healthcare policy are reshaping America's innovation economy.This week on the Making Medicine Podcast, John Stanford sits down with Maria Thacker Goethe, President and CEO of Georgia Life Sciences, to discuss why Georgia has become one of the fastest-growing biotechnology hubs in the United States and what it will take to keep America globally competitive.Fresh off the BIO International Convention, Maria shares how policy conversations have evolved from niche discussions to a central focus for biotech leaders. From clinical trial modernization and manufacturing investments to workforce shortages, drug pricing, and China's expanding biotechnology capabilities, she explains why policy decisions now directly influence innovation, investment, and patient access.This episode covers:🔹 Georgia's rise as a national life sciences and biomanufacturing hub🔹 Why workforce development has become biotech's biggest challenge🔹How universities, industry, and government are building the next generation of talent 🔹China's growing influence in biotechnology and global drug development🔹Drug pricing, innovation, and protecting investment in breakthrough medicines🔹 Operation Trial Blazer and the future of faster clinical trials🔹Why collaboration remains America's greatest competitive advantageOne of the biggest takeaways is that biotechnology is no longer just about scientific discovery. It's about building an ecosystem where policy, workforce, capital, manufacturing, and research all work together. Maria explains why states like Georgia are proving that biotech leadership isn't limited to Boston or San Diego, and why strategic investments in people and infrastructure will determine America's future competitiveness.Whether discussing clinical trial reform, rare disease innovation, or the balance between national security and global scientific collaboration, this conversation highlights how today's policy decisions will shape tomorrow's medical breakthroughs.Watch the full episode and Join the Conversation ⬇️Can Georgia become one of America's top biotech hubs?What is the biggest challenge facing US biotech today: workforce, capital, or policy?Should America focus more on innovation than restrictions to stay globally competitive?Drop your thoughts in the comments below 👇 👍 Like and subscribe for more conversations on biotechnology, healthcare policy, FDA modernization, clinical trials, workforce development, drug pricing, life sciences investment, and healthcare innovation.If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more: X: https://x.com/MakingMedPod Instagram: https://www.instagram.com/makingmedicinepod/ TikTok: https://www.tiktok.com/@makingmedicinepodcast?lang=en LinkedIn: https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=trueTimestamps00:00 Operation Trial Blazer & US Clinical Trials05:01 BIO 2026 and US Biotech Competitiveness08:46 Georgia's Life Sciences Growth 12:07 Building the Next Biotech Hub18:15 Drug Pricing and Biotech Innovation 21:29 Operation Trial Blazer Reforms22:11 China and US Biotech Competition 26:18 Biotech Workforce Development30:06 Why Biotech Needs Skilled Trades33:21 Georgia Life Sciences Summit35:42 Closing ThoughtsDISCLAIMER: We’re reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.#biotech #lifesciences #healthcarepolicy #clinicaltrials #drugdevelopment